



PATENT ATTORNEY DOCKET NO. 50195/008003

Certificate of Mailing: Date of Deposit: \_\_\_\_\_ June 7, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Signature of person mailing correspondence

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

James M. Robl et al.

Art Unit:

1632

Serial No.:

09/988,115

Examiner:

Deborah Crouch

Filed:

November 16, 2001

Customer No.:

21559

Title:

EXPRESSION OF XENOGENOUS (HUMAN) IMMUNOGLOBULINS

IN CLONED, TRANSGENIC UNGULATES

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# **INFORMATION DISCLOSURE STATEMENT**

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of the international search report in the counterpart PCT application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 7 June 2004

Karen L. Elbing, Pl

Reg. No. 35,238

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Sheet 1 of <u>9</u>

**FORM PTO-1449** 

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50195/008003

Serial No.

09/988,115

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicants Filing Date James M. Robl et al.

(Use several sheets if necessary)

November 16, 2001

(37 C.F.R. § 1.98(b))

Group

1632

IDS Filed

June 7, 2004

Customer No.

21559

### U.S. PATENTS

Examiner/]s Initials	Patent No. or Patent Publication No.	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,797,356	01/10/89	Brandt et al.	435	7	12/02/85
	4,847,081	07/11/89	Rice	424	186.1	03/30/87
	4,873,316	10/10/89	Meade et al.	530	412	06/23/87
	4,959,317	09/25/90	Sauer	435	172.3	04/29/87
	4,994,384	02/19/91	Prather et al.	435	172.3	1027/87
	5,021,244 06/04/91 Spaulding		424	561	05/12/89	
	5,057,420	10/15/91	Massey	435	172.2	10/16/90
	5,096,822	03/17/92	Rosenkrans, Jr. et al.	435	388	07/26/90
	5,160,312	11/03/92	Voelkel	600	34	02/06/91
	5,175,384	12/29/92	Krimpenfort et al.	800	2	12/05/88
	5,213,979	05/25/93	First et al.	435	240.2	12/30/87
	5,320,952	06/14/94	Deutch et al.	435	69.1	06/02/93
	5,346,990	09/13/94	Spaulding	530	350	03/12/91
	5,374,544	12/20/94	Schwartz et al.	435	69.1	01/15/92
	5,434,066	07/18/95	Bebee et al.	435	172.3	03/15/94
	5,434,340	07/18/95	Krimpenfort et al.	800	2	07/27/92
	5,453,366	09/26/95	Sims et al.	435	172.3	03/15/93
	5,464,764	11/07/95	Capecchi et al.	435	6	02/04/93
	5,470,560	11/28/95	Martin, Jr.	424	9.2	02/04/94
	5,482,856	01/09/96	Fell, Jr. et al.	435	320.1	04/12/93
	5,487,992	01/30/96	Capecchi et al.	435	172.3	06/28/93
	5,496,720	03/05/96	Susko-Parrish et al.	435	240.2	02/10/93
EVALUNED		<u> </u>	DATE CONCIDENCE			L

**EXAMINER** 

DATE CONSIDERED

Sheet 2 of <u>9</u>

SUBSTITUTE FORM

U.S. DEP COMMERCE PATENT AND TRADEMARK OFFICE

50195/008003 Attorney Docket No.

09/988,115

Serial No.

**Applicants** James M. Robl et al.

Filing Date

November 16, 2001

Group

1632

(37 C.F.R. § 1.98(b))

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

**IDS Filed** 

June 7, 2004

Customer No.

21559

#### U.S. PATENTS

Examiner⊡s Initials	Patent No. or Patent Publication No.	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate
	5,527,674	06/18/96	Guerra et al.	435	6	05/02/94
	5,545,806	08/13/96	Lonberg et al.	800	2	12/16/92
. •	5,545,807	08/13/96	Surani et al.	800	2	08/05/94
	5,565,350	10/15/96	Kmiec	435	172.3	12/09/94
	5,565,362	10/15/96	Rosen	435	320.1	01/24/94
	5,569,825	10/29/96	Lonberg et al.	800	2	12/17/91
	5,583,016	12/10/96	Villeponteau et al.	435	91.3	10/27/94
	5,591,669	01/07/97	Krimpenfort et al.	800	2	05/30/95
	5,612,205	03/18/97	Kay et al.	435	172.3	08/28/91
	5,614,396	03/25/97	Bradley et al.	435	172.3	02/22/94
	5,618,686	04/08/97	Kojima et al.	435	26	03/04/94
	5,625,126	04/29/97	Lonberg et al.	800	2	12/07/94
	5,627,059	05/06/97	Capecchi et al.	800	21	06/05/95
	5,631,153	05/20/97	Capecchi et al.	435	172.3	06/05/95
	5,633,076	05/27/97	DeBoer et al.	435	172.3	11/16/93
	5,633,425	05/27/97	Lonberg et al.	800	2	02/05/92
	5,639,457	06/17/97	Brem et al.	424	184.1	11/15/94
	5,652,373	7/29/97	Reisner	800	11	5/17/93
	5,654,182	08/05/97	Wahl et al.	435	172.1	06/07/95
	5,660,997	08/26/97	Spaulding	435	7.21	06/07/94
	5,661,016	08/26/97	Lonberg et al.	435	172.3	04/26/93
	5,677,177	10/14/97	Wahl et al.	435	325	06/07/95

**EXAMINER** 

DATE CONSIDERED

Sheet 3 of <u>9</u>

SUBSTITUTE FORM PTO

U.S. DEPARTMENDE OMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50195/008003

Serial No.

09/988,115

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Applicants** Filing Date James M. Robl et al. November 16, 2001

(Use several sheets if necessary)

Group

(37 C.F.R. § 1.98(b))

1632

**IDS Filed** 

June 7, 2004

Customer No.

21559

#### U.S. PATENTS

Examiner⊡s Initials	Patent No. or Patent Publication No.	Issue Date or Publication Date	Patent	lee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,679,523	10/21/97	Li et al.		435	6	01/16/96
	5,695,977	12/09/97	Jurka		435	172.3	05/07/96
	5,698,763	12/16/97	Weissmann e	Weissmann et al.		2	06/21/94
	5,721,367	02/24/98	Kay et al.		800	2	06/05/95
	5,733,730	03/31/98	De Lange	De Lange		6	08/25/95
	5,741,957	04/21/98	Deboer et al.		800	2	06/05/95
	5,750,172	05/12/98	Meade et al.		426	580	06/05/95
	5,756,325	05/26/98	Kmiec	Kmiec		172.3	09/09/96
	5,763,240	06/09/98	Zarling et al.	Zarling et al.		172.3	07/14/94
	5,770,422	06/23/98	Collins		435	194	06/23/98
	5,770,429	06/23/98	Lonberg et al.		435	240.2	10/10/95
	5,776,744	07/07/98	Glazer et al.		435	172.3	06/07/95
	5,780,009	07/14/98	Karatzas et al.		424	9.1	01/20/95
	5,780,296	07/14/98	Holloman et al.		435	320.1	01/17/95
	5,789,215	08/04/98	Berns et al.	Berns et al.		172.3	08/07/97
<del>_</del>	5,789,650	08/04/98	Lonberg et al.		800	2	03/18/92
	5,789,655	08/04/98	Prusiner et al.		800	2	06/06/96
	5,801,030	09/01/98	McVey et al.		435	172.3	09/01/95
	5,814,318	09/29/98	Lonberg et al.		424	184.1	07/22/93
	5,821,117	10/13/98	Sandrin et al.		435	320.1	03/15/94
	5,827,690	10/27/98	Meade et al.		435	69.6	12/20/93
EXAMINER				DATE CONSIDERED			·

**EXAMINER** 

DATE CONSIDERED

Sheet 4 of <u>9</u>

SUBSTITUTE (MODIFIED)

U.S. DEPARTMENT OF MMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50195/008003

Serial No.

09/988,115

INFORMATION DISCLOSURE

Applicants

James M. Robl et al.

STATEMENT BY APPLICANT

(Use several sheets if necessary)

Filing Date November 16, 2001

(37 C.F.R. § 1.98(b))

Group

1632

**IDS Filed** 

June 7, 2004

Customer No.

21559

### U.S. PATENTS

5 5	5,830,698 5,837,857 5,843,643 5,843,754 5,849,991 5,849,992 5,874,299	11/03/98 11/17/98 12/01/98 12/01/98 12/15/98	Reff et al.  Villeponteau et al.  Ratner  Susko-Parrish et al.  d'Apice et al.	435 536 435 435 800	69.1 24.31 6 240	03/14/97 06/5/96 02/22/94
5	5,843,643 5,843,754 5,849,991 5,849,992	12/01/98 12/01/98 12/15/98	Ratner Susko-Parrish et al.	435 435	6	
	5,843,754 5,849,991 5,849,992	12/01/98 12/15/98	Susko-Parrish et al.	435		02/22/94
	5,849,991 5,849,992	12/15/98			240	
	5,849,992		d'Apice et al.	800		06/06/95
Ę	. ,	12/15/98		500	2 ,	01/26/95
	5,874,299		Meade et al.	800	2	03/27/95
		02/23/99	Lonberg et al.	435	320.1	02/14/97
	5,876,979	03/02/99	Andrews et al.	435	91.3	06/07/95
	5,877,397	03/02/99	Lonberg et al.	800	2	09/19/94
5	5,891,698	04/06/99	Prieto et al.	435	67.1	05/02/95
	5,945,577	08/31/99	Stice et al.	800	24	01/10/97
	5,952,222	09/14/99	Rosenkrans, Jr. et al.	435	325	08/02/96
6	6,011,197	01/04/00	Streichenko et al.	800	24	01/28/99
6	6,023,010	02/08/00	Krimpenfort et al.	800	2	12/05/96
6	6,030,833	02/29/00	Seebach et al.	435	325	08/02/96
(	6,054,632	04/25/00	Reid	800	6	11/15/96
(	6,066,719	05/23/00	Zapata	530	387.3	03/06/97
(	6,074,853	06/13/00	Pati et al.	435	91.1	08/14/98
	6,077,710	06/20/00	Susko-Parrish et al.	435	375	10/21/98
(	6,091,001	07/18/00	Jakobovits et al.	800	18	03/29/95
	6,147,276	11/14/00	Campbell et al.	800	24	02/19/97
(	6,153,428	11/28/00	Gustafsson et al.	435	325	3/26/96

**EXAMINER** 

DATE CONSIDERED

Sheet \_5\_ of <u>9</u>

SUBSTITUTE FOR (MODIFIED)

DEPARTMEN MERCE ATENT AND TRADEMARK OFFICE

Attorney Docket No.

50195/008003

Serial No.

09/988,115

**Applicants** 

James M. Robl et al.

Filing Date

November 16, 2001

Group

1632

(37 C.F.R. § 1.98(b))

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

**IDS Filed** 

June 7, 2004

Customer No.

21559

#### U.S. PATENTS

Examiner's Initials	Patent No. or Patent Publication No.	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,166,288	12/26/00	Diamond et al.	800	17	07/03/96
	6,183,993	02/06/01	Boyce et al.	435	69.7	06/10/99
	6,194,202	02/27/01	Susko-Parrish et al.	435	325	03/04/96
	6,204,061	03/20/01	Capecchi et al.	435	463	01/09/97
	6,204,431	03/20/01	Prieto et al.	800	14	09/05/97
	6,252,133	06/26/01	Campbell et al.	800	24	02/19/97
	6,258,998	07/10/01	Damiani et al.	800	24	11/24/98
	6,271,436	08/07/01	Piedrahita et al.	800	21	10/10/97
	6,300,129	10/09/01	Lonberg et al.	435	326	12/02/96
	6,395,958	05/28/02	Strelchenko et al.	800	7	07/15/99
	2002/0001842	01/03/02	Chapman	435	449	12/15/00
	2002/0012660	01/31/02	Colman et al.	424	93.21	12/30/99
	2002/0108132	08/08/02	Rapp	800	6	06/08/01

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0546073	09/10/97	EPO			
	EP 0773288	05/14/97	EPO			No
	EP 0843961	05/27/98	EPO			
	EP 1106061	06/13/01	EPO			No
	WO 92/03918	03/19/92	WIPO			No
	WO 93/10227	05/27/93	WIPO			No
	WO 94/02602	02/03/94	WIPO			No

**EXAMINER** 

DATE CONSIDERED

SUBSTITUTE FO

DEPARTMENT OF CONTENT AND TRACE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50195/008003

Serial No.

09/988,115

**Applicants** 

James M. Robl et al.

Sheet 6 of 9

Filing Date

November 16, 2001

Group

1632

**IDS Filed** 

June 7, 2004

Customer No.

21559

### FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 95/33828	12/14/95	WIPO			No
_	WO 96/33735	10/31/96	WIPO			No
	WO 97/07668	03/06/97	WIPO			No
	WO 97/07669	03/06/97	WIPO			No
,	WO 97/07671	03/06/97	WIPO			Yes (provided as EP 0773288)
•	WO 97/13852	04/17/97	WIPO			No
	WO 98/14593	04/09/98	WIPO			No
	WO 98/24884	06/11/98	WIPO			No
	WO 98/24893	06/11/98	WIPO			No
	WO 98/30683	07/16/98	WIPO			No
	WO 98/37183	08/27/98	WIPO	-		No
	WO 98/39416	09/11/98	WIPO			No
	WO 99/21415	05/06/99	WIPO			No
	WO 00/42174	07/20/00	WIPO			No
	WO 00/10383	03/02/00	WIPO			Yes (provided as EP 1106061)
	WO 00/46251	08/10/00	WIPO			No
	WO 00/51424	09/08/00	WIPO			No
	WO 00/67568	11/16/00	WIPO			No
	WO 00/67569	11/16/00	WIPO			No
	WO 00/74477	12/14/00	WIPO			No
	WO 01/23541	04/05/01	WIPO			No
	WO 01/30992	05/03/01	WIPO			No

**EXAMINER** 

DATE CONSIDERED

of \_9

Sheet 7 50195/008003 Attorney Docket No. SUBSTITUTE FORM PTO-1449 DEPA NT OF COMMERCE (MODIFIED) TADEMARK OFFICE Serial No. 09/988,115 Applicants James M. Robl et al. INFORMATION DISCLOSURE Filing Date November 16, 2001 STATEMENT BY APPLICANT (Use several sheets if necessary) Group 1632 (37 C.F.R. § 1.98(b)) **IDS Filed** June 7, 2004 21559 Customer No. FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Publication Class Subclass Translation **Examiner's** Document Country or Initials Number Date Patent Office (Yes/No) WO 01/35735 **WIPO** 05/25/01 No WO 01/73107 10/04/01 **WIPO** No OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Ahearn et al., "Disruption of the Cr2 Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen," Immunity 4:251-262 (1996). Burke et al., "A Cell Free System to Study Reassembly of the Nuclear Envelope at the End of Mitosis," Cell 44:639-652 (1986). Cibelli et al., "Bovine Chimeric Offspring Produced By Transgenic Embryonic Stem Cells Generated From Somatic Cell Nuclear Transfer Embryos," Theriogenology p. 236. Cibelli et al., "Cloned Transgenic Calves Produced from Nonquiescent Fetal Fibroblasts, " Science 280:1256-1258 Collas et al., "Lipophilic Organizing Structures of Sperm Nuclei Target Membrane Vesicle Binding and Are Incorporated Into the Nuclear Envelope," Dev. Biol. 169:123-135 (1995). Collas, "Sequential PKC- and Cdc2-Mediated Phosphorylation Events Elicit Zebrafish Nuclear Envelope Disassembly," J. Cell Sci. 112:977-987 (1999). Collas et al., "The A-Kinase Anchoring Protein, AKAP95, Is A Multivalent Protein With A Key Role In Chromatin Condensation At Mitosis," J. Cell Biol. 147:1167-1179 (1999). Cubizolles et al., "pEg7, A New Xenopus Protein Required For Mitotic Chromosome Condensation in Egg Extracts," J. Cell Biol. 143:1437-1446 (1998). Denning et al., "Deletion of the  $\alpha(1,3)$ Galactosyl Transferase (GGTA1) Gene and the Prion Protein (PrP) Gene in Sheep," Nat. Biotechnol. 19:559-562 (2001). Ehrenstein et al., "Targeted Gene Disruption reveals a Role for Natural Secretory IgM in the Maturation of the Primary Immune Response," Proc. Natl. Acad. Sci., USA 95:10089-10093 (1998). Erlandsson et al., "Mice with an Inactivated joining chain Locus Have Perturbed IgM Secretion," Eur. J. Immunol. 28:2355-2365 (1998). Goldman et al., "Enhanced Human Cell Engraftment in Mice Deficient in RAG2 and the Common Cytokine Receptor Gamma Chain," Br. J. Haematol. 103:335-342 (1998). Guidos et al., "Development of CD4+CD8+ Thymocytes in RAG-Deficient Mice Through a T Cell Receptor β Chain-Independent Pathway," J. Exp. Med. 181:1187-1195 (1995). DATE CONSIDERED **EXAMINER** EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

3 201 0 5 204 2		Sheet 8 of 9					
SUBSTITUTE FORM PTO-1449 DEPARTMENT OF COMMERCE	Attorney Docket No.	50195/008003					
(MODIFIED) PAGE TRADEMARK OFFICE	Serial No.	09/988,115					
	Applicants	James M. Robl et al.					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	November 16, 2001					
(Use several sheets if necessary)	Group	1632					
(37 C.F.R. § 1.98(b))	IDS Filed	June 7, 2004					
	Customer No.	21559					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE,	DATE, PLACE OF PUBLIC	CATION)					
Ishida et al., "Production of a Diverse Repertoire of Human Immunol. 42:143-150 (1998).	Antibodies In Genetically E	Engineered Mice," Microbiol.					
Jonak et al., "Manipulation of Human B Cells to Confer Immortality," Hum. Antibodies Hybridomonas 3:177-18 (1992).							
Joziasse et al., "Bovine Alpha 1 3-Galactosyltransferase: Identification of Homologous Sequences in Human Genom	solation and Characterizat c DNA," J. Biol. Chem. 26	tion of a cDNA Clone. 4:14290-14297 (1989).					
Joziasse et al., "Characterization of an α13-Galactosyltrar organized As A Processed Pseudogene," <i>J. Biol. Chem.</i> 26		ıman Chromosome 12 That Is					
Kitamura et al., "A B Cell-Deficient Mouse by Targeted Disr Chain Gene," <i>Nature</i> 350:423-426 (1991).	Kitamura et al., "A B Cell-Deficient Mouse by Targeted Disruption of the Membrane Exon of the Immunoglobulin Chain Gene," <i>Nature</i> 350:423-426 (1991).  Knight et al., "Genetic Engineering of Bovine Ig. Construction and Characterization of Hapten-Binding Bovine/Murine Chimeric IgE, IgA, IgG1, IgG2, and IgG3 Molecules," <i>J. Immunol.</i> 140:3654-3659 (1988).						
Kuroiwa et al., "Manipulation of Human Minichromosomes t Inserts," Nat. Biotechnol. 18:1086-1090 (2000).	Kuroiwa et al., "Manipulation of Human Minichromosomes to Carry Greater Than Megabase-Sized Chromosome Inserts," <i>Nat. Biotechnol.</i> 18:1086-1090 (2000).						
Lansford et al., "Ig Heavy Chain Class Switching in Rag-De	ficient Mice," Int. Immunol.	10:325-332 (1998).					
Lohka et al., "Formation In Vitro of Sperm Pronuclei and Mi Components," Science 220:719-721 (1983).	otic Chromosomes Induce	d By Amphibian Ooplasmic					
Lohka et al., "Induction of Nuclear Envelope Breakdown, Cl Cell-Free Extracts," J. Cell Biol. 101:518-523 (1985).	romosome Condensation	And Spindle Formation In					
Loupart et al., "Differential Stability of a Human Mini-Chrom (1998).	osome in Mouse Cell Line	s," Chromosoma 107:255-259					
Martin et al., "Engraftment of Human Lymphocytes and Thy Progression of Lymphocytic Infiltration," J. Clin. Endocrinol.							
Mazurier et al., "A Novel Immunodeficient Mouse Model—Find Double Mutants—Requiring Exogenous Cytokine Administr J. Interferon cytokine Res. 19:533-541 (1999).							
Miake-Lye et al., "Induction of Early Mitotic Events in a Cell-	Free System," Cell 41:165	i-175 (1985).					
Mocikat, "Improving the Expression of Chimeric Antibodies Cells," J. Immunol. Methods 225:185-189 (1999).	Following Homologous Re	combination in Hybridoma					
Newport, "Nuclear Reconstitution In Vitro: Stages of Assem	bly Around Protein-Free D	NA," Cell 48:205-217 (1987).					
Polejaeva et al., "New Advances In Somatic Cell Nuclear To 53:117-126 (2000).	ansfer: Application In Tran	nsgenesis," Theriogenology					
EXAMINER DATE O	ONSIDERED						
EXAMINER: Initial citation considered. Draw line through citation if not in conform with the next communication to applicant.	nformance and not consid	ered. Include copy of this					

Sheet 9 of 9

SUBSTITUTE	FORM PTO-1449 U.S. DEPARAMENT OF COMMI		Attorney Docket No.	50195/008003			
(MODIFIED)	TRADEMARK OF	FFICE	Serial No.	09/988,115			
			Applicants	James M. Robl et al.			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 16, 2001			
	(Use several sheets if necessary)		Group	1632			
(37 C.F.R. § 1	.98(b))		IDS Filed	June 7, 2004			
			Customer No.	21559			
	OTHER DOCUMENTS (INCLUDING AUTHOR, 1	TITLE, DA	TE, PLACE OF PUBLIC	ATION)			
	Rideout et al., "Nuclear Cloning and Epigenetic Repr	rogrammi	ng of the Genome," Scie	nce 293:1093-1098 (2001).			
	Schnieke et al., "Human Factor IX Transgenic Sheep Fibroblasts," Science 278:2130-2133 (1997).	Produce	d By Transfer of Nuclei f	From Transfected Fetal			
	Shen et al., "Human Mini-Chromosomes in Mouse Embryonal Stem Cells," Hum. Mol. Genet. 6:1375-1382 (199						
	Srikumaran et al., "Bovine X Mouse Hybridomas that Secrete Bovine Immunoglobulin G1," Science 220:522-524 (1983).						
	Steen et al., "A-Kinase Anchoring Protein (AKAP)95 D2/Eg7 For Chromosome Condensation In Mitotic Ex						
	Steen et al., "Recruitment of Protein Phosphatase 1 AKAP149 Is A Pre-Requisite For Nuclear Lamina As						
	Suprynowicz et al., "A Fractionated Cell-Free System 103:2073-2081 (1986).	for Anal	ysis of Prophase Nuclear	Disassembly," J. Cell Biol.			
	Tomizuka et al., "Double Trans-Chromosomic Mice: Maintenance of Two Individual Human Chromosome Fragments Containing Ig Heavy and Kappa Loci and Expression of Fully Human antibodies," <i>Proc. Natl. Acad. Sci, USA</i> 97:722-727 (2000).						
	Wilson et al., "A Trypsin-Sensitive Receptor On Membrane Vesicles Is Required For Nuclear Envelope Formation I Vitro," J. Cell Biol. 107:57-68 (1988).						
	Yahata et al., "Reconstitution of Immune Systems in Hematopoietic Progenitor Cells," Immunol. Lett. 62:1			terleukin-12-Induced Splenic			
EXAMINER	C	ATE CO	NSIDERED				
	itial citation considered. Draw line through citation if next communication to applicant.	ot in confe	ormance and not conside	ered. Include copy of this			